



FINANCIAL TEAR SHEET

Corporate Profile

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Sanfilippo disorder, Batten disease, Fanconi anemia and other rare disorders.

Primary IR Contact

Andre'a Lucca
 Director of Communications
 PlasmaTech
 Biopharmaceuticals, Inc.
Phone: 212-786-6208
E-mail:
 alucca@plasmatechbio.com

Stock Performance

ABEO (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$14.20
Change (%)	▲ 0.55 (4.03%)
Volume	402,192
52 Week Low	\$7.50
Market Cap	\$654,425,840
Rolling EPS	-0.74
PE Ratio	0
Shares Outstanding	47,943,285



Data as of August 21, 2018 4:00 p.m. ET

Recent Press Releases & Upcoming Events

August 9, 2018
Abeona Therapeutics Reports Second
Quarter 2018 Financial Results and
Business Highlights

July 26, 2018
Abeona Therapeutics Announces
Leadership Appointments with Max Colao
as Chief Commercial Officer

June 6, 2018
Abeona Therapeutics Announces
Upcoming Presentation at Jefferies 2018
Global Healthcare Conference

There are currently no events scheduled.

SEC Filings

Filing Date	Form
August 20, 2018	8-K
August 17, 2018	424B5
August 16, 2018	8-K
August 9, 2018	8-K

Corporate Governance

Data provided by Nasdaq. Minimum 15 minutes delayed.